Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5333
Abstract: Metastatic castration‐resistant prostate cancer (mCRPC) is a genetically heterogeneous disease with a poor prognosis. The prevalence of mutations in homologous recombination repair (HRR) pathway genes, including BRCA1/2, as well as treatment patterns and clinical outcomes,…
read more here.
Keywords:
prostate cancer;
resistant prostate;
castration resistant;
metastatic castration ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/5830475
Abstract: Patients with BRCA1/2 mutations (BRCAm), loss-of-function mutations in other homologous recombination repair (HRRm) genes, or tumors that are homologous recombination deficiency positivity (HRD+) demonstrate a robust response to PARPi therapy. We conducted a systematic literature…
read more here.
Keywords:
oncology;
recombination;
hrd;
mutations homologous ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221083050
Abstract: Background: Mutations in homologous recombination (HR) and Fanconi anemia (FA) genes may predispose to pancreatic cancer (PC) and enable the prediction of sensitivity to platinum-based chemotherapy. FOLFIRINOX is a standard treatment option for non-selected PC…
read more here.
Keywords:
therapy;
platinum;
mutations homologous;
fanconi anemia ... See more keywords